

## DR. RAHUL ROY CHOWDHURY

Consultant Gynaec Oncologist

### Qualification

MBBS | MRCOG (London) | FRCOG (UK)

### Fellowship & Membership

- Association of Gynecologic Oncologists of India (AGOI)
- Fellowship from the Royal College of Obstetricians and Gynaecologists (FRCOG)
- Indian Society of Clinical Oncology and Cancer Physicians (ISCCP)
- Founding Member of Kolkata Gynecology Trials and Translational Research Group (KolGO Trg)

### Field of Expertise

- Specialising in gynaecological oncology, focusing on the diagnosis and treatment of gynaecological cancers.
- Expertise in Pelvic and Upper Abdominal Surgeries for the management of various gynaecological and gynaecological conditions.
- Proficiency in performing Peritonectomies, a surgical procedure involving the removal of the peritoneum lining.
- Skilled in conducting Laparoscopic Procedures tailored for the management of endometrial cancers, ensuring precise and minimally invasive treatment options.

### Languages Spoken

- English
- Bengali
- Hindi

### Awards & Achievements

- Local mentor for the Country Training of International Gynec Cancer Society Fellowship
- Invited delegate to the 1st Endometrial Endometrial Cancer Consensus Conference for Clinical Research (ECCC-CR) on November 2nd and 3rd, 2023 in Seoul, Korea. LMIC (India, Nepal, Bangladesh) representative for Endometrial Cancer Consensus meeting on standards in Research on Endometrial Cancer

### Talks & Publications

- Ghosh DD, Chowdhury R R, Dutta R, Mukhopadhyay I, Mukhopadhyay A, Roychoudhury S. In-silico analysis of

TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.

<https://doi.org/10.1016/j.gore.2023.101209>

- Mandal P, Bhattacharjee B, Sen S, Bhattacharya A, Saha SS, Chowdhury RR, Mondal NR, Chakrabarty B, Chatterjee T, Roy S, Sengupta S. Predominance of genomically defined A lineage of HPV16 over D lineage in Indian patients from eastern India with squamous cell carcinoma of the cervix in association with distinct oncogenic phenotypes. *Transl Oncol.* 2021 Oct 27;15(1):101256. doi: 10.1016/j.tranon.2021.101256. Epub ahead of print. PMID: 34717279; PMCID: PMC8564679.
- Kurtz JE, GebSKI V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer InterGroup (GCIg) symptom benefit committee. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIg symptom benefit committee. *Gynecol Oncol.* 2021 May;161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. PMID: 33612336.
- Poster presentation
- Mukhopadhyay A, Ghosh T, Bhattacharjee D, Chakraborty D, Gupta , Roychowdhury I, Chatterjee P, Vemekar M, Chowdhury RR, Intermittent PARP Inhibitor Regimen In Ovarian Cancer (IPIROC): Origin and Feasibility Of Implementing A Proof Of Concept Exploratory Study.18 October 2023 IGCS Abstracts.